This product is intended for laboratory and research purposes only and is not intended for human consumption
The terms and conditions, if they exist at all, bury subscription details in fine print
Supports energy production, fat metabolism, and endurance
During the perimenopausal and postmenopausal periods, declining oestrogen levels are associated with increased central adiposity, insulin resistance, and a higher risk of metabolic syndrome
Many are seeking long-term wellness solutions rather than quick fixes
Sources Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Diabetes, Obesity and Metabolism, Neeland et al., 2024 Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss